ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

A TGF-β signaling-related lncRNA signature for prediction of glioma prognosis, immune microenvironment, and immunotherapy response

Duan, Wei-Wei; Yang, Li-Ting; Liu, Jian; Dai, Zi-Yu; Wang, Ze-Yu; Zhang, Hao; Zhang, Xun; Liang, Xi-Song; Luo, Peng; Zhang, Jian; Liu, Zao-Qu; Zhang, Nan; Mo, Hao-Yang; Qu, Chun-Run; Xia, Zhi-Wei*; Cheng, Quan*南方医科大学; 哈尔滨医科大学; 郑州大学; 1
CNS Neuroscience & Therapeutics2023-10-18DOI: 10.1111/cns.14489
8阅读
引用收藏
分享

摘要

Aims: The dysregulation of TGF-beta signaling is a crucial pathophysiological process in tumorigenesis and progression. LncRNAs have diverse biological functions and are significant participants in the regulation of tumor signaling pathways. However, the clinical value of lncRNAs related to TGF-beta signaling in glioma is currently unclear.Methods: Data on glioma's RNA-seq transcriptome, somatic mutation, DNA methylation data, and clinicopathological information were derived from the CGGA and TCGA databases. A prognostic lncRNA signature was constructed by Cox and LASSO regression analyses. TIMER2.0 database was utilized to deduce immune infiltration characteristics. "ELMER v.2" was used to reconstruct TF-methylation-gene regulatory network. Immunotherapy and chemotherapy response predictions were implemented by the TIDE algorithm and GDSC database, respectively. In vitro and in vivo experiments were conducted to verify the results and clarify the regulatory mechanism of lncRNA.Results: In glioma, a TGF-beta signaling-related 15-lncRNA signature was constructed, including AC010173.1, HOXA-AS2, AC074286.1, AL592424.1, DRAIC, HOXC13-AS, AC007938.1, AC010729.1, AC013472.3, AC093895.1, AC131097.4, AL606970.4, HOXC-AS1, AGAP2-AS1, and AC002456.1. This signature proved to be a reliable prognostic tool, with high risk indicating an unfavorable prognosis and being linked to malignant clinicopathological and genomic mutation traits. Risk levels were associated with different immune infiltration landscapes, where high risk was indicative of high levels of macrophage infiltration. In addition, high risk also suggested better immunotherapy and chemotherapy response. cg05987823 was an important methylation site in glioma progression, and AP-1 transcription factor family participated in the regulation of signature lncRNA expression. AGAP2-AS1 knockdown in in vitro and in vivo experiments inhibited the proliferation, migration, and invasion of glioma cells, as well as the growth of glioma, by downregulating the expression levels of NF-kappa B and ERK 1/2 in the TGF-beta signaling pathway.Conclusions: A prognostic lncRNA signature of TGF-beta signaling was established in glioma, which can be used for prognostic judgment, immune infiltration status inference, and immunotherapy response prediction. AGAP2-AS1 plays an important role in glioma progression.

学科与关键词

关键词
gliomaimmune infiltrationimmunotherapylncRNAprognosisTGF-beta
相关
加载中…
  • Construction and Verification of a Novel Pyroptosis-Related lncRNA Signature Associated with Immune Landscape in Gliomas
    Feng, Xiaoqiang; Chen, Yuehua; Liu, Xuanyu; Zhong, Zhihui; Liu, Yanjun*Journal of Oncology, 2022, 2022: 7043431.
  • Identification of a cellular senescence-related-lncRNA (SRlncRNA) signature to predict the overall survival of glioma patients and the tumor immune microenvironment
    Liu, Qing; Bao, Hongbo; Zhang, Sibin; Song, Tianjun; Li, Chenlong; Sun, Guiyin; Sun, Xiaoyang; Fu, Tianjiao; Wang, Yujie; Liang, Peng*Frontiers in Genetics, 2023, 14: 1096792.
  • Developing an Immune-Related Signature for Predicting Survival Rate and the Response to Immune Checkpoint Inhibitors in Patients With Glioma
    Zhang, Sibin; Xiao, Xu; Wang, Yu; Song, Tianjun; Li, Chenlong; Bao, Hongbo; Liu, Qing; Sun, Guiyin; Sun, Xiaoyang; Su, Tianqi; Fu, Tianjiao; Wang, Yujie; Liang, Peng*Frontiers in Genetics, 2022, 13: 899125.被引 2
查看全部 →

发表信息

论文状态
公开发表
期刊
CNS Neuroscience & Therapeutics
发表日期
2023-10-18
DOI
10.1111/cns.14489
语言
ENGLISH
成果收录
SCIE
资助标注
This work was supported by the National Natural Science Foundation of China (NO.82073893, NO.81903015), Hunan Provincial Natural Science Foundation of China (NO.2022JJ20095, NO.2019JJ50780), Hunan Provincial Health Committee Foundation of China (NO.2022040 [82073893, 81903015]; National Natural Science Foundation of China [2022JJ20095, 2019JJ50780]; Hunan Provincial Natural Science Foundation of China [202204044869, 2022YK04]; Hunan Provincial Health Committee Foundation of China; High Performance Computing Center of Central South University

作者

  • D

    Duan, Wei-Wei (第一作者)

  • Y

    Yang, Li-Ting

查看全部 16 位作者收起作者
  • L

    Liu, Jian

    1 · hunan univ chinese med

  • D

    Dai, Zi-Yu

  • W

    Wang, Ze-Yu

  • Z

    Zhang, Hao

  • Z

    Zhang, Xun

  • L

    Liang, Xi-Song

  • L

    Luo, Peng

    southern med univ

  • Z

    Zhang, Jian

    southern med univ

  • L

    Liu, Zao-Qu

    1 · zhengzhou univ

  • Z

    Zhang, Nan

    harbin med univ

  • M

    Mo, Hao-Yang

  • Q

    Qu, Chun-Run

  • X

    Xia, Zhi-Wei (通讯)

    changsha med univ

  • C

    Cheng, Quan (通讯)

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417